Michael Conick Hanley
Net worth: 47 017 $ as of 2024-04-29
Profile
Michael Conick Hanley worked as the Chief Business Officer at Spyre Therapeutics, Inc. from 2022 to 2023.
Prior to that, he was the Chief Commercial Officer & Vice President at Esteve Pharmaceuticals S.A.
from 2018 to 2019 and the Group Vice President-Marketing at Horizon Therapeutics Plc from 2015 to 2017.
Hanley completed his undergraduate degree at Notre Dame University and earned an MBA from Kellogg School of Management.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SPYRE THERAPEUTICS, INC
0.00% | 2023-02-22 | 1,448 ( 0.00% ) | 47 017 $ | 2024-04-29 |
Former positions of Michael Conick Hanley
| Companies | Position | End |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Corporate Officer/Principal | 2023-04-13 |
Esteve Pharmaceuticals S.A.
 Esteve Pharmaceuticals S.A. Pharmaceuticals: OtherHealth Technology Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain. | Corporate Officer/Principal | 2019-08-31 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Sales & Marketing | 2017-05-31 |
Training of Michael Conick Hanley
| Kellogg School of Management | Masters Business Admin |
| Notre Dame University | Undergraduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Esteve Pharmaceuticals S.A.
Esteve Pharmaceuticals S.A. Pharmaceuticals: OtherHealth Technology Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain. | Health Technology |
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
- Stock Market
- Insiders
- Michael Conick Hanley
